|
|
Volumn 3, Issue 2, 2001, Pages 131-140
|
|
Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
COLLAGEN;
ENDOSTATIN;
PEPTIDE FRAGMENT;
RECOMBINANT PROTEIN;
ARTICLE;
BIOASSAY;
BIOPSY;
HUMAN;
METHODOLOGY;
MULTIMODALITY CANCER THERAPY;
NEOPLASM;
PHASE 1 CLINICAL TRIAL;
VASCULARIZATION;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC AGENTS;
BIOPSY;
CLINICAL TRIALS, PHASE I;
COLLAGEN;
COMBINED MODALITY THERAPY;
ENDOSTATINS;
ENDPOINT DETERMINATION;
HUMANS;
NEOPLASMS;
PEPTIDE FRAGMENTS;
RECOMBINANT PROTEINS;
RESEARCH DESIGN;
|
|
EID: 0035291168
PISSN: 15233790
EISSN: None
Source Type: Journal
DOI: 10.1007/s11912-001-0013-8 Document Type: Article |
|
Times cited : (51)
|
|
References (0)
|
